<code id='9BA86CC7C1'></code><style id='9BA86CC7C1'></style>
    • <acronym id='9BA86CC7C1'></acronym>
      <center id='9BA86CC7C1'><center id='9BA86CC7C1'><tfoot id='9BA86CC7C1'></tfoot></center><abbr id='9BA86CC7C1'><dir id='9BA86CC7C1'><tfoot id='9BA86CC7C1'></tfoot><noframes id='9BA86CC7C1'>

    • <optgroup id='9BA86CC7C1'><strike id='9BA86CC7C1'><sup id='9BA86CC7C1'></sup></strike><code id='9BA86CC7C1'></code></optgroup>
        1. <b id='9BA86CC7C1'><label id='9BA86CC7C1'><select id='9BA86CC7C1'><dt id='9BA86CC7C1'><span id='9BA86CC7C1'></span></dt></select></label></b><u id='9BA86CC7C1'></u>
          <i id='9BA86CC7C1'><strike id='9BA86CC7C1'><tt id='9BA86CC7C1'><pre id='9BA86CC7C1'></pre></tt></strike></i>

          fashion

          fashion

          author:comprehensive    Page View:79
          Photograph of a person wearing blue gloves counts money. -- health business coverage from STAT
          Adobe

          WASHINGTON — Doctors are staring down a cut to their Medicare pay next year, and while the news has united them in outrage, it’s also turned one specialty against another.

          Medicare officials last week announced its major annual update to the way the program pays physicians. Along with other changes, it includes a policy that will boost payments to specialties that rely on evaluating and managing patients, as opposed to those that focus on procedures. But in Medicare, boosting payments in one area almost always means cutting them somewhere else. So to pay for that, doctors across the country will see a roughly 3% cut to a factor that determines how much Medicare pays them for caring for seniors.

          advertisement

          The change has pitted certain specialties against primary care doctors. A host of surgeons’ groups, including the American College of Surgeons, plainly criticized family physicians in a recent letter to Medicare, saying there’s no “valid justification” for the boost and calling it an “inappropriate” overpayment.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more
          J&J to buy cancer drug developer Ambrx Biopharma
          J&J to buy cancer drug developer Ambrx Biopharma

          AP/RichardDrewJohnson&JohnsonsaidMondaythatitwouldpurchaseAmbrxBiopharmafornearly$2billion,picki

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Illumina names Agilent executive as new CEO

          AdobeIllumina,thelargestmakerofDNA-sequencingtechnologyandastoriednameinthebiotechnologyindustry,nam